Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encenicline for Cognitive Impairment in Schizophrenia
NCT01716975Phase 3Completed
- Sponsor
- FORUM Pharmaceuticals
- Start
- Oct 2012
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of encenicline in schizophrenia (3 arms), sponsored by FORUM Pharmaceuticals. Primary endpoints: MATRICS Consensus Cognitive Battery at Day 182, Schizophrenia Cognition Rating Scale at Day 182 and 1 more. Started Oct 2012; status: completed.
02
Drugs
encenicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01716975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716975.